Phaseline

Targets › TUSC2

TUSC2 (Tumor suppressor candidate 2): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

May function as a tumor suppressor, inhibiting colony formation, causing G1 arrest and ultimately inducing apoptosis in homozygous 3p21.3 120-kb region-deficient cells. (UniProt, O75896)

Open in Phaseline: the race on TUSC2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Genprexquaratusugene ozeplasmid
TUSC2 gene therapy - interrupts cell signaling pathways, reestablishes cancer cell death p
TUSC2Phase 1Small Cell Lung Cancer Extensive Stage; Carcinoma, Non-Small Cell LungDec 2027

Conditions

Small Cell Lung Cancer Extensive Stage (1) Carcinoma, Non-Small Cell Lung (1)

Modalities

mixed (1)

Companies

Genprex (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.